NO882763L - Humant apolipoprotein ai og variantform av samme uttrykt i escherichia coli. - Google Patents

Humant apolipoprotein ai og variantform av samme uttrykt i escherichia coli.

Info

Publication number: NO882763L
Authority: NO; Norway
Prior art keywords: apoai; protein; met; sequence; ser
Prior art date: 1986-10-23

Application number

NO882763A

Other languages

English (en)

Norwegian (no)

Other versions

NO882763D0 (no

Inventor

Rolando Lorenzetti

Lucia Monaco

Marco Soria

Raffaele Palomba

Antonella Isacchi

Paolo Sarmientos

Original Assignee

Erba Carlo Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-10-23

Filing date

1988-06-22

Publication date

1988-08-22

1988-06-22 Application filed by Erba Carlo Spa filed Critical Erba Carlo Spa

1988-06-22 Publication of NO882763D0 publication Critical patent/NO882763D0/no

1988-08-22 Publication of NO882763L publication Critical patent/NO882763L/no

Links

241000588724 Escherichia coli Species 0.000 title claims description 17
108010059886 Apolipoprotein A-I Proteins 0.000 title description 97
102000005666 Apolipoprotein A-I Human genes 0.000 title description 77
108090000623 proteins and genes Proteins 0.000 claims abstract description 167
102000004169 proteins and genes Human genes 0.000 claims abstract description 138
230000027455 binding Effects 0.000 claims abstract description 35
239000013604 expression vector Substances 0.000 claims abstract description 30
230000002068 genetic effect Effects 0.000 claims abstract description 21
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 19
101100379247 Salmo trutta apoa1 gene Proteins 0.000 claims abstract description 18
102000005936 beta-Galactosidase Human genes 0.000 claims abstract description 16
108010005774 beta-Galactosidase Proteins 0.000 claims abstract description 16
125000000729 N-terminal amino-acid group Chemical group 0.000 claims abstract description 8
238000002965 ELISA Methods 0.000 claims abstract 4
150000001413 amino acids Chemical class 0.000 claims description 43
239000013612 plasmid Substances 0.000 claims description 37
238000000034 method Methods 0.000 claims description 25
108010088160 Staphylococcal Protein A Proteins 0.000 claims description 9
102000007592 Apolipoproteins Human genes 0.000 claims description 8
108010071619 Apolipoproteins Proteins 0.000 claims description 8
108010013369 Enteropeptidase Proteins 0.000 claims description 8
125000003275 alpha amino acid group Chemical group 0.000 claims description 8
241000701959 Escherichia virus Lambda Species 0.000 claims description 5
101100521383 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) prp-5 gene Proteins 0.000 claims description 5
108091005804 Peptidases Proteins 0.000 claims description 5
102000035195 Peptidases Human genes 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 3
244000084296 Hernandia moerenhoutiana Species 0.000 claims description 2
235000010044 Hernandia moerenhoutiana Nutrition 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims description 2
LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 claims 1
239000004480 active ingredient Substances 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
238000011084 recovery Methods 0.000 claims 1
239000013598 vector Substances 0.000 abstract description 15
201000001320 Atherosclerosis Diseases 0.000 abstract description 5
208000024172 Cardiovascular disease Diseases 0.000 abstract description 3
235000018102 proteins Nutrition 0.000 description 119
108010010234 HDL Lipoproteins Proteins 0.000 description 47
102000015779 HDL Lipoproteins Human genes 0.000 description 47
210000004027 cell Anatomy 0.000 description 46
235000001014 amino acid Nutrition 0.000 description 37
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 31
239000012634 fragment Substances 0.000 description 22
108091034117 Oligonucleotide Proteins 0.000 description 14
230000001580 bacterial effect Effects 0.000 description 14
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
102000037865 fusion proteins Human genes 0.000 description 12
108020001507 fusion proteins Proteins 0.000 description 12
239000000499 gel Substances 0.000 description 12
108020004414 DNA Proteins 0.000 description 11
239000000872 buffer Substances 0.000 description 11
235000012000 cholesterol Nutrition 0.000 description 11
238000004458 analytical method Methods 0.000 description 10
238000010276 construction Methods 0.000 description 10
239000003446 ligand Substances 0.000 description 10
230000035772 mutation Effects 0.000 description 10
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 9
239000000020 Nitrocellulose Substances 0.000 description 9
FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 9
150000002632 lipids Chemical class 0.000 description 9
229920001220 nitrocellulos Polymers 0.000 description 9
229940079938 nitrocellulose Drugs 0.000 description 9
239000002773 nucleotide Substances 0.000 description 9
125000003729 nucleotide group Chemical group 0.000 description 9
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
239000002609 medium Substances 0.000 description 8
239000000203 mixture Substances 0.000 description 8
239000002245 particle Substances 0.000 description 8
239000000725 suspension Substances 0.000 description 8
102000004895 Lipoproteins Human genes 0.000 description 7
108090001030 Lipoproteins Proteins 0.000 description 7
239000002299 complementary DNA Substances 0.000 description 7
208000029078 coronary artery disease Diseases 0.000 description 7
238000003119 immunoblot Methods 0.000 description 7
238000000746 purification Methods 0.000 description 7
239000012581 transferrin Substances 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
108091028043 Nucleic acid sequence Proteins 0.000 description 6
241001494479 Pecora Species 0.000 description 6
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
108090000901 Transferrin Proteins 0.000 description 6
102000004338 Transferrin Human genes 0.000 description 6
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
238000011534 incubation Methods 0.000 description 6
239000000463 material Substances 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
239000007983 Tris buffer Substances 0.000 description 5
229940088598 enzyme Drugs 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
239000000284 extract Substances 0.000 description 5
210000002540 macrophage Anatomy 0.000 description 5
150000003904 phospholipids Chemical class 0.000 description 5
229920002401 polyacrylamide Polymers 0.000 description 5
108091008146 restriction endonucleases Proteins 0.000 description 5
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
230000032258 transport Effects 0.000 description 5
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
102000006410 Apoproteins Human genes 0.000 description 4
108010083590 Apoproteins Proteins 0.000 description 4
108020004705 Codon Proteins 0.000 description 4
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
108091081024 Start codon Proteins 0.000 description 4
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
230000029087 digestion Effects 0.000 description 4
238000001502 gel electrophoresis Methods 0.000 description 4
108010064060 high density lipoprotein receptors Proteins 0.000 description 4
102000054823 high-density lipoprotein particle receptor activity proteins Human genes 0.000 description 4
230000003902 lesion Effects 0.000 description 4
239000008188 pellet Substances 0.000 description 4
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
239000000523 sample Substances 0.000 description 4
238000012163 sequencing technique Methods 0.000 description 4
239000000243 solution Substances 0.000 description 4
230000009870 specific binding Effects 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
238000013519 translation Methods 0.000 description 4
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
108091026890 Coding region Proteins 0.000 description 3
102000053602 DNA Human genes 0.000 description 3
102100029727 Enteropeptidase Human genes 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
102000009109 Fc receptors Human genes 0.000 description 3
108010087819 Fc receptors Proteins 0.000 description 3
229920001213 Polysorbate 20 Polymers 0.000 description 3
229920002684 Sepharose Polymers 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
238000001042 affinity chromatography Methods 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000004202 carbamide Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000010367 cloning Methods 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
238000010828 elution Methods 0.000 description 3
238000000605 extraction Methods 0.000 description 3
239000012894 fetal calf serum Substances 0.000 description 3
230000006870 function Effects 0.000 description 3
238000002523 gelfiltration Methods 0.000 description 3
210000003494 hepatocyte Anatomy 0.000 description 3
238000009396 hybridization Methods 0.000 description 3
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
238000005259 measurement Methods 0.000 description 3
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
239000002243 precursor Substances 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
230000009466 transformation Effects 0.000 description 3
239000012588 trypsin Substances 0.000 description 3
FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 2
IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
108010004103 Chylomicrons Proteins 0.000 description 2
102000012410 DNA Ligases Human genes 0.000 description 2
108010061982 DNA Ligases Proteins 0.000 description 2
102000004594 DNA Polymerase I Human genes 0.000 description 2
108010017826 DNA Polymerase I Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
102000003960 Ligases Human genes 0.000 description 2
108090000364 Ligases Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
102000016943 Muramidase Human genes 0.000 description 2
108010014251 Muramidase Proteins 0.000 description 2
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
102000003992 Peroxidases Human genes 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
239000004365 Protease Substances 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
102000007238 Transferrin Receptors Human genes 0.000 description 2
108010033576 Transferrin Receptors Proteins 0.000 description 2
239000013504 Triton X-100 Substances 0.000 description 2
229920004890 Triton X-100 Polymers 0.000 description 2
229920004929 Triton X-114 Polymers 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
239000000956 alloy Substances 0.000 description 2
229910045601 alloy Inorganic materials 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
239000002585 base Substances 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
238000009835 boiling Methods 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
238000005520 cutting process Methods 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
238000006911 enzymatic reaction Methods 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000006192 iodination reaction Methods 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
230000004576 lipid-binding Effects 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
239000004325 lysozyme Substances 0.000 description 2
229960000274 lysozyme Drugs 0.000 description 2
235000010335 lysozyme Nutrition 0.000 description 2
239000003550 marker Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
235000013336 milk Nutrition 0.000 description 2
239000008267 milk Substances 0.000 description 2
210000004080 milk Anatomy 0.000 description 2
231100000219 mutagenic Toxicity 0.000 description 2
230000003505 mutagenic effect Effects 0.000 description 2
108091027963 non-coding RNA Proteins 0.000 description 2
102000042567 non-coding RNA Human genes 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
238000010186 staining Methods 0.000 description 2
238000003756 stirring Methods 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
230000005030 transcription termination Effects 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
238000012800 visualization Methods 0.000 description 2
238000005406 washing Methods 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
102000057234 Acyl transferases Human genes 0.000 description 1
108700016155 Acyl transferases Proteins 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
-1 CPA-AI Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
102000003670 Carboxypeptidase B Human genes 0.000 description 1
108090000087 Carboxypeptidase B Proteins 0.000 description 1
102000000496 Carboxypeptidases A Human genes 0.000 description 1
108010080937 Carboxypeptidases A Proteins 0.000 description 1
108010059081 Cathepsin A Proteins 0.000 description 1
102000005572 Cathepsin A Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
108700010070 Codon Usage Proteins 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
108090000204 Dipeptidase 1 Proteins 0.000 description 1
241001522878 Escherichia coli B Species 0.000 description 1
241001646716 Escherichia coli K-12 Species 0.000 description 1
108010014173 Factor X Proteins 0.000 description 1
102000008857 Ferritin Human genes 0.000 description 1
108050000784 Ferritin Proteins 0.000 description 1
238000008416 Ferritin Methods 0.000 description 1
102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
101100109141 Mesocricetus auratus APOAI gene Proteins 0.000 description 1
102000007474 Multiprotein Complexes Human genes 0.000 description 1
108010085220 Multiprotein Complexes Proteins 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108020005091 Replication Origin Proteins 0.000 description 1
101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
101000582398 Staphylococcus aureus Replication initiation protein Proteins 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
102000009843 Thyroglobulin Human genes 0.000 description 1
108010034949 Thyroglobulin Proteins 0.000 description 1
101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 description 1
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
241001672648 Vieira Species 0.000 description 1
SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000003513 alkali Substances 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000036523 atherogenesis Effects 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
102000006635 beta-lactamase Human genes 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
244000309466 calf Species 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000004182 chemical digestion Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000000287 crude extract Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
239000000539 dimer Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
210000002472 endoplasmic reticulum Anatomy 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
NTNZTEQNFHNYBC-UHFFFAOYSA-N ethyl 2-aminoacetate Chemical compound CCOC(=O)CN NTNZTEQNFHNYBC-UHFFFAOYSA-N 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
230000004927 fusion Effects 0.000 description 1
229960002743 glutamine Drugs 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000005802 health problem Effects 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
125000001165 hydrophobic group Chemical group 0.000 description 1
208000006575 hypertriglyceridemia Diseases 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000026045 iodination Effects 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
238000002955 isolation Methods 0.000 description 1
101150066555 lacZ gene Proteins 0.000 description 1
230000008604 lipoprotein metabolism Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
239000012160 loading buffer Substances 0.000 description 1
235000020121 low-fat milk Nutrition 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
238000001000 micrograph Methods 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
238000012856 packing Methods 0.000 description 1
108010091212 pepstatin Proteins 0.000 description 1
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
108010083127 phage repressor proteins Proteins 0.000 description 1
239000012071 phase Substances 0.000 description 1
229960003531 phenolsulfonphthalein Drugs 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000008057 potassium phosphate buffer Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000008569 process Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000006152 selective media Substances 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000002356 single layer Substances 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
238000010257 thawing Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
229960002175 thyroglobulin Drugs 0.000 description 1
238000012546 transfer Methods 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
108010087967 type I signal peptidase Proteins 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
239000011800 void material Substances 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Urology & Nephrology (AREA)
General Chemical & Material Sciences (AREA)
Cardiology (AREA)
Toxicology (AREA)
Animal Behavior & Ethology (AREA)
Physics & Mathematics (AREA)
Heart & Thoracic Surgery (AREA)
Pharmacology & Pharmacy (AREA)
Vascular Medicine (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Steroid Compounds (AREA)

NO882763A 1986-10-23 1988-06-22 Humant apolipoprotein ai og variantform av samme uttrykt i escherichia coli. NO882763L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB868625435A GB8625435D0 (en)	1986-10-23	1986-10-23	Human apolipoprotein ai
PCT/EP1987/000621 WO1988003166A1 (en)	1986-10-23	1987-10-21	Human apolipoprotein ai and variant form of the same expressed in escherichia coli

Publications (2)

Publication Number	Publication Date
NO882763D0 NO882763D0 (no)	1988-06-22
NO882763L true NO882763L (no)	1988-08-22

Family

ID=10606217

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO882763A NO882763L (no)	1986-10-23	1988-06-22	Humant apolipoprotein ai og variantform av samme uttrykt i escherichia coli.

Country Status (16)

Country	Link
EP (1)	EP0267703B1 (de)
JP (2)	JP2706247B2 (de)
KR (1)	KR890700163A (de)
CN (1)	CN87107991A (de)
AT (1)	ATE64619T1 (de)
AU (1)	AU8230587A (de)
CZ (1)	CZ761587A3 (de)
DE (1)	DE3770915D1 (de)
ES (1)	ES2044950T3 (de)
GB (1)	GB8625435D0 (de)
IL (1)	IL84229A0 (de)
NO (1)	NO882763L (de)
PT (1)	PT85977B (de)
WO (1)	WO1988003166A1 (de)
YU (1)	YU193887A (de)
ZA (1)	ZA877911B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8712540D0 (en) *	1987-05-28	1987-07-01	Ucb Sa	Expression of human proapolipoprotein a-i
GB8717791D0 (en) *	1987-07-28	1987-09-03	Baralle F E	Immunoassay method
IT1229996B (it) *	1989-04-20	1991-09-20	Cesare Sirtori	Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
AU662885B2 (en) *	1990-06-07	1995-09-21	Scripps Research Institute, The	APO AI polypeptides, antibodies, and immunoassays
US5292646A (en) *	1991-02-06	1994-03-08	Genetics Institute, Inc.	Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
US5270181A (en) *	1991-02-06	1993-12-14	Genetics Institute, Inc.	Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
CA2070058A1 (en) *	1991-05-31	1992-12-01	Robert A. Gadski	Vectors and methods for assaying the regulation of apolipoprotein ai synthesis
WO1993000443A1 (en) *	1991-06-26	1993-01-07	Bio-Technology General Corp.	Purification of recombinant apolipoprotein e from bacteria
US5408038A (en) *	1991-10-09	1995-04-18	The Scripps Research Institute	Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides
SE9103701D0 (sv)	1991-12-13	1991-12-13	Kabi Pharmacia Ab	Apolipoprotein
SE9203753D0 (sv) *	1992-12-11	1992-12-11	Kabi Pharmacia Ab	Expression system for producing apolipoprotein ai-m
SE9500778D0 (sv) *	1995-03-03	1995-03-03	Pharmacia Ab	Process for producing a protein
SE9603068D0 (sv)	1996-08-23	1996-08-23	Pharmacia & Upjohn Ab	Process for purifying a protein
SE9603303D0 (sv)	1996-09-11	1996-09-11	Pharmacia & Upjohn Ab	Process for purifying a protein
SE9603304D0 (sv)	1996-09-11	1996-09-11	Pharmacia & Upjohn Ab	Process for purifying a compound
UA81216C2 (en) *	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
WO2002038609A2 (en) *	2000-11-10	2002-05-16	Proteopharma Aps	Apolipoprotein conjugates
AU2002362612B2 (en)	2001-09-28	2007-11-15	Cedars-Sinai Medical Center	Prevention and treatment of restenosis by local administration of drug
US7052849B2 (en)	2001-11-23	2006-05-30	Syn X Pharma, Inc.	Protein biopolymer markers predictive of insulin resistance
CN1870894B (zh) *	2003-10-20	2011-08-10	埃斯普里昂治疗公司	用于治疗和预防急性冠状动脉综合征的药物制剂、方法和给药方案
WO2005097206A2 (en)	2004-04-06	2005-10-20	Cedars-Sinai Medical Center	Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein a-i and apolipoprotein a-i milano
US7759315B2 (en)	2005-03-09	2010-07-20	Csl Behring Ag	Treatment of inflammatory conditions of the intestine
DK1964571T3 (da)	2007-03-01	2012-08-13	Csl Ltd	Behandling af endothelial dysfunktion hos diabetespatienter
WO2011143362A1 (en)	2010-05-11	2011-11-17	Esperion Therapeutics, Inc.	Dimeric oxidation-resistant apolipoprotein a1 variants
SG10201801372YA (en)	2011-02-07	2018-04-27	Cerenis Therapeutics Holding S A	Lipoprotein complexes and manufacturing and uses thereof
CN112940090B (zh) *	2021-03-18	2023-02-24	广州康盛生物科技股份有限公司	耐受辐照灭菌及高效消毒的蛋白a免疫吸附介质

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0217822B1 (de) *	1985-02-13	1993-05-12	Scios Nova Inc.	Menschlicher metallothionein ii-promotor in säugetierexpressionssystemen

1986
- 1986-10-23 GB GB868625435A patent/GB8625435D0/en active Pending
1987
- 1987-10-20 IL IL84229A patent/IL84229A0/xx unknown
- 1987-10-21 ZA ZA877911A patent/ZA877911B/xx unknown
- 1987-10-21 AU AU82305/87A patent/AU8230587A/en not_active Abandoned
- 1987-10-21 DE DE8787309318T patent/DE3770915D1/de not_active Expired - Fee Related
- 1987-10-21 JP JP62506754A patent/JP2706247B2/ja not_active Expired - Fee Related
- 1987-10-21 WO PCT/EP1987/000621 patent/WO1988003166A1/en unknown
- 1987-10-21 AT AT87309318T patent/ATE64619T1/de not_active IP Right Cessation
- 1987-10-21 EP EP87309318A patent/EP0267703B1/de not_active Expired - Lifetime
- 1987-10-21 ES ES87309318T patent/ES2044950T3/es not_active Expired - Lifetime
- 1987-10-22 YU YU01938/87A patent/YU193887A/xx unknown
- 1987-10-22 CN CN198787107991A patent/CN87107991A/zh active Pending
- 1987-10-22 PT PT85977A patent/PT85977B/pt unknown
- 1987-10-22 CZ CS877615A patent/CZ761587A3/cs unknown
1988
- 1988-06-21 KR KR1019880700705A patent/KR890700163A/ko not_active Application Discontinuation
- 1988-06-22 NO NO882763A patent/NO882763L/no unknown
1997
- 1997-05-26 JP JP9134703A patent/JP2777126B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IL84229A0 (en)	1988-03-31
JPH02500797A (ja)	1990-03-22
ATE64619T1 (de)	1991-07-15
JP2706247B2 (ja)	1998-01-28
KR890700163A (ko)	1989-03-10
YU193887A (en)	1989-06-30
PT85977B (en)	1990-01-19
ZA877911B (en)	1988-04-25
JPH1052287A (ja)	1998-02-24
PT85977A (en)	1987-11-01
DE3770915D1 (de)	1991-07-25
CN87107991A (zh)	1988-09-21
ES2044950T3 (es)	1994-01-16
WO1988003166A1 (en)	1988-05-05
NO882763D0 (no)	1988-06-22
EP0267703B1 (de)	1991-06-19
CZ761587A3 (en)	1994-11-16
GB8625435D0 (en)	1986-11-26
JP2777126B2 (ja)	1998-07-16
AU8230587A (en)	1988-05-25
EP0267703A1 (de)	1988-05-18

Publication	Publication Date	Title
NO882763L (no)	1988-08-22	Humant apolipoprotein ai og variantform av samme uttrykt i escherichia coli.
Morrow et al.	1999	Functional characterization of apolipoprotein E isoforms overexpressed in Escherichia coli
JP3577311B2 (ja)	2004-10-13	インスリン様成長因子結合タンパク質の製造
Liu et al.	2003	Neph1 and nephrin interaction in the slit diaphragm is an important determinant of glomerular permeability
US5721114A (en)	1998-02-24	Expression system for producing apolipoprotein AI-M
EP0369943B1 (de)	1994-09-28	Bindeproteine für insulinähnliche Wachstumsfaktoren
JP4943410B2 (ja)	2012-05-30	線維芽細胞増殖因子様ポリペプチド
PT87562B (pt)	1992-09-30	Processo para expressao de proapolipoproteina a-i humana
JP3082941B2 (ja)	2000-09-04	ヒト・アポリポ蛋白質ａｉおよびａｉ―ミラノの酵母での発現
Sasaki et al.	2018	Functional characterization of recombinant snake venom rhodocytin: rhodocytin mutant blocks CLEC‐2/podoplanin‐dependent platelet aggregation and lung metastasis
Sacchettini et al.	1990	Expression of rat intestinal fatty acid binding protein in E. coli and its subsequent structural analysis: a model system for studying the molecular details of fatty acid-protein interaction
WO1988003170A1 (en)	1988-05-05	Pulmonary hydrophobic surfactant-associated proteins
Ojala et al.	2013	Progressive reactive lymphoid connective tissue disease and development of autoantibodies in scavenger receptor A5–deficient mice
JP2849517B2 (ja)	1999-01-20	新規生理活性物質エピモルフィン、それをコードする遺伝子及びエピモルフィンに対する抗体
JPH09511399A (ja)	1997-11-18	アファミン：ヒト血清アルブミン様タンパク質
Charbonnier et al.	2001	Overexpression, refolding, and purification of the histidine-tagged outer membrane efflux protein OprM of Pseudomonas aeruginosa
EP1474438A2 (de)	2004-11-10	Verfahren zur herstellung eines gereinigten rekombinanten humanen uteroglobins zur behandlung von entzündlichen und fibrotischen erkrankungen
JPH03504438A (ja)	1991-10-03	アンドロジェンレセプターを含むｄｎａ結合蛋白質
JPH05506141A (ja)	1993-09-16	アンドロゲン受容体を含むｄｎａ結合蛋白質
Ray et al.	1990	Alteration in the receptor binding specificity of human growth hormone by genomic exon exchange
Matsunaga	2014	Apolipoprotein AI mutations and clinical evaluation
US5759816A (en)	1998-06-02	Expression vectors containing λPL promoter and T1 T2 rRNA termination sequence plasmids containing the vectors hosts containing the plasmids and related methods
JPH06293800A (ja)	1994-10-21	新規生理活性物質エピモルフィン、それをコードする遺伝子及びエピモルフィンに対する抗体
Bruni	2024	Alan J. Waring, Larry M. Gordon, H. William Taeusch
Nagao et al.	1988	Expression of Bovine α s1-casein cDNA in Escherichia coli